GoodRx revises $155 million incremental term loan OID to 99.75

By Sara Rosenberg

New York, Oct. 25 – GoodRx tightened the original issue discount on its fungible $155 million incremental first-lien term loan (B2/B) due October 2025 to 99.75 from talk in the range of 99 to 99.5, according to a market source.

Pricing on the incremental term loan is Libor plus 300 basis points with a step-down to Libor plus 275 bps at 4x net first-lien leverage and a 0% Libor floor, in line with existing term loan pricing.

The incremental term loan has 101 soft call protection for six months.

Goldman Sachs Bank USA, Barclays, BofA Securities, Inc., Credit Suisse Securities (USA) LLC, KKR Capital Markets, Citizens Bank and SunTrust Robinson Humphrey Inc. are the leads on the deal.

Recommitments were scheduled to be due at 3:30 p.m. ET on Friday, the source said.

Proceeds will be used with cash on hand to refinance an existing second-lien term loan.

GoodRx is a Santa Monica, Calif.-based operator of a prescription drug price comparison and coupon platform.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.